Integrum Unveils Global Marketing Strategy at AOPA National Assembly
Mölndal, Sweden, September 4, 2025 – Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B), the provider of the OPRA™ Implant System, announced the rollout of a new global marketing strategy at the American Orthotic & Prosthetic Association’s (AOPA) National Assembly in Orlando, FL. Central to this initiative is BondedMatrix™ - a coined term designed to capture and convey the OPRA™ Implant System’s distinct ability to integrate soft tissue and bone enabling long-term outcomes to patients, clinicians, and healthcare partners worldwide.
BondedMatrix™ refers to the biologically integrated barrier that connects the skin and bone at the penetration site after healing — a result achievable by design with OPRA due to its unique surgical technique and implant design. While this capability has long been inherent to OPRA, the new designation provides a clearer way to communicate its benefits globally.
“This initiative is about creating a common language that makes OPRA™’s advantages more accessible to clinicians, prosthetists, and patients,” said Jeffrey Zanni, President, Integrum Inc. “We are proud to introduce this globally, as defining BondedMatrix™ equips our partners with a powerful way to communicate why OPRA™ remains the most advanced solution in bone-anchored prosthetics.”
Rickard Brånemark, MD, inventor of the OPRA Implant System and founder of Integrum, has refined this surgical technique with global partners since 1990. Over 1,000 implants have been placed worldwide, helping amputees regain mobility and independence.
"BondedMatrix™ is not a new feature, but a new way of defining a key component behind Integrum’s decades of successful osseointegration."said Dr. Jason Souza, Director of the Advanced Amputation Program at Ohio State University and a leading expert in bone-anchored prosthetics. “Patients want a dependable and dry skin-implant interface - a BondedMatrix. The OPRA Implant System is the only one that can reliably deliver it. I'm excited that patients now have a way to ask for it."
Integrum are presenting this strategy at booth #931 during AOPA 2025, including live discussions and educational resources. On Thursday evening, the company will host an educational dinner meetingfeaturing Jason Souza, MD, Orthoplastic Surgeon at Ohio State University, highlighting patient outcomes and clinical experience with OPRA and BondedMatrix™.
For more information about BondedMatrix™ visit www.bondedmatrix.com.
For more information, please contact:
Jeffrey Zanni, President US
Email: Jeff.Zanni@integrum.se
Phone: +1 617-839-1600
Jörgen Svanström, CFO
Phone: +46 (0) 7073 496 60,
Email: jorgen.svanstrom@integrum.se
Certified Adviser
The Company's Certified Adviser is DNB Carnegie Investment Bank AB.
About Integrum
Integrum AB is a publicly traded company (INTEG B: Nasdaq First North Growth Market) based outside of Gothenburg, Sweden, with a U.S. subsidiary in San Francisco. Since 1990, its OPRA™ Implant System has helped improve the quality of life for hundreds of people who are amputees by directly attaching a prosthesis to the bone and musculoskeletal system, therefore eliminating the need for a socket. Based on osseointegration, the bone-anchored implant system offers a range of benefits, including improved mobility and function, enhanced comfort, reduced pressure, a stable attachment and more. The OPRA™ Implant System was approved by the U.S. Food and Drug Administration (FDA) in 2020 and is the only FDA-approved bone-anchored implant system specifically designed for use in amputees available in the U.S. Today, Integrum continues to perform research and develop custom-made medical device solutions in close collaboration with scientists and clinicians. To learn more, please visit https://integrum.se/.